ATE223719T1 - Schnellauflösende efavirenz-kapseln oder tabletten durch verwendung von super-zersetzern - Google Patents

Schnellauflösende efavirenz-kapseln oder tabletten durch verwendung von super-zersetzern

Info

Publication number
ATE223719T1
ATE223719T1 AT99916286T AT99916286T ATE223719T1 AT E223719 T1 ATE223719 T1 AT E223719T1 AT 99916286 T AT99916286 T AT 99916286T AT 99916286 T AT99916286 T AT 99916286T AT E223719 T1 ATE223719 T1 AT E223719T1
Authority
AT
Austria
Prior art keywords
decompositors
tablets
super
fast dissolving
capsules
Prior art date
Application number
AT99916286T
Other languages
English (en)
Inventor
William T Makooi-Morehead
John D Buehler
Brian R Landmann
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE223719(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE223719T1 publication Critical patent/ATE223719T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99916286T 1998-04-07 1999-04-01 Schnellauflösende efavirenz-kapseln oder tabletten durch verwendung von super-zersetzern ATE223719T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07
PCT/US1999/007228 WO1999051239A1 (en) 1998-04-07 1999-04-01 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Publications (1)

Publication Number Publication Date
ATE223719T1 true ATE223719T1 (de) 2002-09-15

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916286T ATE223719T1 (de) 1998-04-07 1999-04-01 Schnellauflösende efavirenz-kapseln oder tabletten durch verwendung von super-zersetzern

Country Status (27)

Country Link
US (2) US6238695B1 (de)
EP (1) EP1067936B1 (de)
JP (1) JP2002510634A (de)
KR (1) KR100634253B1 (de)
CN (1) CN1146419C (de)
AR (1) AR019031A1 (de)
AT (1) ATE223719T1 (de)
AU (1) AU756422B2 (de)
BR (1) BR9908810A (de)
CA (1) CA2321523C (de)
CZ (1) CZ300850B6 (de)
DE (1) DE69902893T2 (de)
DK (1) DK1067936T3 (de)
EA (1) EA003217B1 (de)
EE (1) EE04391B1 (de)
ES (1) ES2181417T3 (de)
HU (1) HU228498B1 (de)
IL (1) IL138078A (de)
NO (1) NO325824B1 (de)
NZ (1) NZ507566A (de)
PL (1) PL194309B1 (de)
PT (1) PT1067936E (de)
SK (1) SK284655B6 (de)
TW (1) TW576741B (de)
UA (1) UA72207C2 (de)
WO (1) WO1999051239A1 (de)
ZA (1) ZA200004313B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (de) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz enthaltende gepresste Tablettenformulierung
AU753241C (en) * 1998-06-11 2003-05-08 Pharmacia & Upjohn Company Tablet formation
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
WO2003045327A2 (en) * 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
ES2308136T3 (es) * 2003-01-14 2008-12-01 Gilead Sciences, Inc. Composiciones y procedimientos para la politerapia antiviral.
US8021682B2 (en) * 2004-08-13 2011-09-20 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US20070026073A1 (en) * 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
BRPI0620705A2 (pt) * 2005-12-14 2011-11-22 Cipla Ltd formulação farmacêutica em uma forma única de dosagem unitária, produto farmacêutico, uso de uma formulação farmacêutico e uso de um inibidor de transcriptase-reversa de nucleosìdeo ou derivado fisiologicamente funcional do mesmo e um inibidor de transcriptase-reversa de nucleotìdeo ou derivado fisiologicamente funcional do mesmo
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
US20080069876A1 (en) * 2006-09-14 2008-03-20 Moore Ryan G Method for preparing solid dosage forms that form a paste, cream or gel when diluted for final use
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (de) * 2007-01-26 2009-12-02 Isp Investments Inc. Verfahren zur herstellung einer formulierung für sprühgetrocknete produkte
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2009026257A2 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
US20120295898A1 (en) 2010-01-27 2012-11-22 Mark Richard Underwood Antiviral Therapy
KR20130076818A (ko) * 2010-04-20 2013-07-08 시플라 리미티드 약학 조성물
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
IN2013MU03370A (de) 2013-10-25 2015-09-25 Cipla Ltd
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017029225A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0301006B1 (de) 1986-04-01 1992-05-06 The Upjohn Company Methylprednisolon/natriumcarboxymethylstärke-tablettenmischung
AU638421B2 (en) * 1989-04-28 1993-07-01 Daiichi Pharmaceutical Co., Ltd. An anti-human immunodeficiency virus composition
SG49770A1 (en) * 1992-07-08 1998-06-15 Santen Oy Pharmaceutical preparation
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz

Also Published As

Publication number Publication date
PL343421A1 (en) 2001-08-13
PT1067936E (pt) 2002-12-31
KR100634253B1 (ko) 2006-10-16
EE04391B1 (et) 2004-12-15
SK284655B6 (sk) 2005-08-04
NO20005043D0 (no) 2000-10-06
AU3463799A (en) 1999-10-25
UA72207C2 (uk) 2005-02-15
EE200000589A (et) 2002-04-15
IL138078A (en) 2005-12-18
BR9908810A (pt) 2000-12-19
US6238695B1 (en) 2001-05-29
CZ20003571A3 (cs) 2001-01-17
SK14612000A3 (sk) 2001-07-10
CA2321523C (en) 2008-10-07
TW576741B (en) 2004-02-21
NO20005043L (no) 2000-10-06
JP2002510634A (ja) 2002-04-09
EA003217B1 (ru) 2003-02-27
HUP0101517A2 (hu) 2001-11-28
DE69902893T2 (de) 2003-04-30
AU756422B2 (en) 2003-01-09
IL138078A0 (en) 2001-10-31
CN1296412A (zh) 2001-05-23
US20010012518A1 (en) 2001-08-09
WO1999051239A1 (en) 1999-10-14
HU228498B1 (en) 2013-03-28
ZA200004313B (en) 2002-01-30
AR019031A1 (es) 2001-12-26
CZ300850B6 (cs) 2009-08-26
NO325824B1 (no) 2008-07-21
DK1067936T3 (da) 2003-02-17
KR20010042473A (ko) 2001-05-25
HUP0101517A3 (en) 2002-11-28
US6555133B2 (en) 2003-04-29
ES2181417T3 (es) 2003-02-16
CA2321523A1 (en) 1999-10-14
EP1067936B1 (de) 2002-09-11
DE69902893D1 (de) 2002-10-17
EA200001030A1 (ru) 2001-04-23
PL194309B1 (pl) 2007-05-31
CN1146419C (zh) 2004-04-21
EP1067936A1 (de) 2001-01-17
NZ507566A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
ATE223719T1 (de) Schnellauflösende efavirenz-kapseln oder tabletten durch verwendung von super-zersetzern
DE69922857D1 (de) Rechnersicherheit durch Virusuntersuchung
DE69829400D1 (de) Passive immunisierung gegen durch clostridium difficile verursachte krankheit
DE69821488D1 (de) Gegenstromreaktor
DE60018505D1 (de) Vertraute Überprüfung von Rechnerprogrammodulen
DE60042256D1 (de) Schlüsselverteilung durch eine speicheranordnung
NO20004316L (no) Meta azasykliske aminobenzosyreforbindelser og derivater derav som er integrinatantagonister
FI83346B (fi) Kalander, saerskilt en superkalander.
ATE242735T1 (de) Indirekt betätigbarer verschluss
NO20010219L (no) Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel
DE69907022D1 (de) Tablettenspender
NO20005857D0 (no) Nye blandinger
DE69916278T2 (de) Kernbrennstofftablette
DK1074250T3 (da) Sukkerovertrukne tabletter
DE69732715D1 (de) Tachykinin antagoniste
DE69838634D1 (de) Mechanismus um gleichzeitig zwei seiten wasserabweisend zu machen
DE69828263D1 (de) Durch tazaroten induziertes gen
DE69929474D1 (de) Eine softwareentwicklungsstruktur
ID27048A (id) Metode untuk mencegah mrp1
DE69711927D1 (de) Rechnerbetriebsmittelverriegelung
FR2812118B1 (fr) Polarisateur de neutrons
FR2736085B1 (fr) Cremone anti-panique, communement appelee cremone pompier
DE69804286D1 (de) Teilerschaltung zum Teilen durch gerade Zahlen
DE60044865D1 (de) Testen von geschütztem material
FI20002373A (fi) Sydänrakenne

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1067936

Country of ref document: EP